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Cutaneous squamous cell carcinoma (cSCC) is an increasing public health problem. It is a primary malignant skin tumor with
Malpighian differentiation and together with basal cell carcinoma is classified among nonmelanoma skin cancers (NMSCs). cSCC
usually occurs on photoexposed areas, such as the head, the neck, and the extremities, and its incidence increases with age. Invasive
forms of this skin tumor tend to be more aggressive showing a higher metastatic potential, usually regarding regional lymph nodes.
Treatment options for invasive cSCCs include both surgical and nonsurgical options. The therapeutic choice depends on several
factors, such as anatomic location, risk factors for tumor recurrence, age, and health status of the patient.This review aims to provide
an overview of the current evidence on therapeutic surgical and nonsurgical management of invasive cSCC.
1. Introduction
Cutaneous squamous cell carcinoma (cSCC) is the second
most common form of NMSC after basal cell carcinoma. In
2017, the American Joint Committee on Cancer revised the
staging guidelines of this tumor reflecting the recent evidence
on high risk clinicopathologic features [1].
The most significant modification from the prior seventh
edition is the introduction of cSCC from a general chapter for
the entire body to a head and neck-specific cutaneous malig-
nancies chapter, thus addressing NMSCs of the head and
neck aswell as thosemalignancies that arise from themucosal
surfaces of the upper aerodigestive tract and salivary glands.
This skin tumor, in fact, is characterized by the malignant
proliferation of keratinising cells which mimics those of the
spinous layer of the epidermis [2–4]. These cells can migrate
beyond the level of the dermoepidermal junction, in the der-
mis or deeper, and may develop both de novo and from pre-
cursor lesions, such as AK and Bowen’s diseases, thus becom-
ing invasive forms. These forms are aggressive and express
a highermetastatic potential, usually regarding regional lymph
nodes.
Clinically, it usually presents as a firm, flesh colored or
erythematous, hyperkeratotic enlarging plaque or papule, but
it may also be pigmented or verrucous (Figures 1, 2(a) and
2(b)). Sometimes cSCC may appear as an ulcer, a smooth
nodule or a tricky cutaneous horn (Figures 3(a) and 3(b)).
cSCC arises frequently in field of cancerization rather
than de novo. Genetic alterations are recognizable both in
tumoral cells and in elements without histological atypia,
so microenvironment of premalignant lesions can influence
their progression to invasive and metastatic cSCC [5, 6]. The
genetic background also influences malignant potential of
cSCC, as Genome-wide association studies (GWAS) have
identified genetic loci associated with cSCC risk, and single
nucleotide polymorphisms (SNP) of the class II human
leukocyte antigen region associations with tumor develop-
ment have recently been investigated [6].
cSCC results from the malignant proliferation of epider-
mal keratinocytes due to complex biological events involving
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Figure 1: Squamous cell carcinoma presenting on forehead in the
form of enlarging ulcer.
(a)
(b)
Figure 2: Clinical (a) and dermoscopic (b) aspects of a firm, erythe-
matous hyperkeratotic Squamous Cell Carcinoma.
multiple factors [5, 6]. Ultraviolet radiations (UVs), particu-
larly UVB (290–320 nm) and UVA (320–340 nm) radiations,
have a pivotal role in tumor pathogenesis. Sun exposure
and artificial sources of UV, like PUVA therapy, are major
epidemiologic risk factors for cSCC [7]. Genetic disorders
such as xeroderma pigmentosum and chronic skin damaged
areas including scars, ulcers, burn sites, and chronic sun
exposure are related to increased incidence of skin cancer
spread. Recent evidence displayed that immunosuppressed
patients tend to develop multiple and more aggressive cSCC;
precisely patients undergoing solid organ transplantation
have 65-fold higher risk of developing cSCC than the general
population [5, 7, 8]. It is also important to evaluate the loca-
tion of the primary skin lesions.
Tumors located on lips and ears are associatedwith higher
rates of local recurrence and distant metastasis (20–50%); in
these cases lateral-cervical, submandibular, submental, and
intraparotid lymph nodes are frequently involved [6].
Tumor thickness is currently considered to be the most
important independent predictor of metastasis in cSCC. Per-
ineural invasion increases the risk of recurrence, according
to the thickness of the nerves affected and to the presence
of clinical and/or radiologic signs of invasion. 0.1mm is the
cutoff for nerve diameter associated with poor short-term
and long-term prognosis.
cSCC has also been described in melanoma patient
undergoing BRAF inhibitors (BRAFi) treatment.These drugs
induce therapeutic responses in metastatic melanoma but
also develop secondary malignant skin tumors. This is ex-
plained in part by “paradoxical ERK activation,” or the hyper-
activation of ERK signaling by BRAF inhibitor in BRAFwild-
type cells [9, 10].
A trend of increasing incidence for cSCC, since the 1960s,
has been registered [11], probably related to the ageing of the
population and to the change of sun exposure behaviour;
in fact, 80% of people affected are older than 60 years. It is
estimated that over 700.000 new cases of cSCC are diagnosed
annually in the USA [3]; moreover the cSCC incidence has
been predicted to increase more than 50% by 2030 [12, 13].
2. Treatment Options
Treatment options for invasive SCC include both surgical and
nonsurgical modalities. The therapeutic choice depends on
several factors, such as anatomic location, risk factors for
tumor recurrence, age, and health status of the patient [14].
The TNM classification, developed by AJCC/IUAC/UICC,
which is used for all skin cancers except melanoma, is not
suitable for SCC, since it is not considered in the multiple
prognostic criteria identified in the literature.
The principal aim of treatment is to completely remove
or destroy the tumor, while preserving the function and the
aesthetic appearance.
Surgery still represents the gold standard approach and
may be combined with plastic reconstruction, Mohs’ micro-
graphic surgery (MMS), electrodessication, or curettage.
Nonsurgical options for invasive cSCC include topical
chemotherapy, topical immune responsemodifiers, radiother-
apy, and systemic chemotherapy.The latter is usually reserved
for patients with metastatic lesions.
Such approaches are recommended onlywhen the patient
refuses surgery or surgery cannot be performed.
2.1. Surgery. Complete surgical removal with histopatho-
logical control of excision margins represents the first line
treatment for cSCC (Figures 4(a) and 3(b)). The main aim of
surgery is to obtain complete tumor excisionwhile preserving
the function and a satisfactory cosmetic result, particularly in
sensitive areas such as lips, noise, ears, and natural orifices.
Surgery is also indicated with adjuvant radiation to control
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Figure 3:Clinical (a) anddermoscopic (b) images of cutaneous horn.
regional disease in the presence of nodal metastases and per-
ineural invasion. However predicting the risk of developing
lymph node metastases from cSCC is difficult and clinical
data about the utility of sentinel node biopsy (SNB) is lacking
in literature. This leads physicians to be uncertain on which
patients require staging and what procedure to use in nodal
staging. So further studies are needed to define the role of
SLNB in patients with cSCC.
As for the surgical treatment, two techniques can be
performed: standard surgical excision with postoperative
margin assessment or micrographic surgery and its variants:
MMS and “slow Mohs” technique.
Standard excision allows confirming the histological
diagnosis of cSCC and verifying the complete removal of the
tumor. Excision margins refer to the minimum amount of
healthy skin over the visible limits of the tumor that should
be removed to assure the complete tumor eradication [15].
Excision margins should be adapted to the clinical size and
degree of tumor aggression. A prospective study involving
141 cases of cSCC showed that a 4mm margin allows for
completely removal of 95% of low risk tumors,measuring less
(a)
(b)
Figure 4: Before (a) and after (b) surgical excision of hyperkeratotic
nodular squamous cell carcinoma.
than 2 cm in diameter [16]. Larger tumors (>2 cm) require
more than 6mm excision margins. Moreover, in tumors
with high risk prognostic factors, such as moderate or poor
differentiation, recurrent tumor, perineural invasion, exten-
sion deep into the subcutaneous fat, and/or location on the
ear or lip, more than 6mm margins are recommended, in-
dependently of the clinical diameter [17].
2.2. Microscopically Controlled Surgery (Mohs’ Micrographic
Surgery). Microscopically controlled surgery (MCS) or
Mohs’ micrographic surgery (MMS) was introduced in the
first half of the 20th century as an alternative to standard exci-
sion, electrodessication, and radiation therapy for cutaneous
carcinomas.
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MMS consists of the removal of serial horizontal sections
of the tumor margins, in order to minimize the risk of re-
currence [18].Themain aim of MMS is to completely remove
the tumor while sparing as many tissues as possible.
At first, the tumor is surgically removed with minimal
margins; then thin horizontal sections (2mm) of the sur-
rounding skin are topographically marked and removed and
histologically analyzed in an extemporaneous fashion. If the
margins are positive for tumor cells, localized reexcisions are
performed until the area is completely tumor free.
Tumor slices are examined intraoperatively using frozen
sections (Mohs surgery) or on paraffin sections (“slowMohs”
surgery).
The disadvantages of MMS consist of a longer duration of
the operation and higher costs.
MMS demonstrated a 5-year recurrence rate for cSCC
compared to standard surgery of 3% versus 8%, respectively,
and should be recommended in selected cases [19, 20]:
(i) In high risk cSCCs as first line treatment [21]
(ii) In low risk cSCCs when the margins are positive after
standard excision with 4–6mmmargins [21]
(iii) When complete excision is difficult to achieve [22]
(iv) In case of high risk of recurrence
(v) For cSCCs localized in sensitive sites such central
facial region and periorificial areas, nose and lips [22]
(vi) In cases where surgical excision could cause func-
tional impairment [23]
(vii) In tumors with aggressive histological growth pat-
terns [24].
2.3. Radiotherapy. Radiotherapy is based on the administra-
tion of ionizing radiations for skin cancer treatment through
two different techniques: external radiotherapy and intersti-
tial curietherapy (brachytherapy).
External radiotherapy uses superficial or deep X-rays,
gamma rays (telecobalt), or electron beams (linear accelera-
tors) [7]. Different regimens have been used up to date, which
vary in terms of duration, fractioning, and total dose
administered [25]. The NCCN recommended an algorithm
consisting of a total dose of 45–50Gy in fractions of 2.5–3Gy
for SCCs<2 cm in diameter and 60–66Gy in fractions of 2Gy
or 50–60Gy in fractions of 2.5 Gy for tumors >2 cm [26].
Radiation field involves both the tumor and a safety
margin of 1–1,5 cm of surrounding skin.
Radiotherapy is recommended for cSCC in the following
cases:
(i) It is recommended as an alternative to surgery when
patient refuses surgery or patient’s conditions con-
traindicate surgery [27].
(ii) It is recommended as a primary treatment for inoper-
able SCCs or in the adjuvant setting [27, 28].
(iii) It is recommended for debilitated patients who can-
not tolerate extensive surgery.
(iv) It is recommended when surgical excision would be
extremely disfiguring.
(v) In recurrent cSCCs, radiotherapy should be consid-
ered as adjuvant therapy to improve tumor control.
(vi) It is recommended in management of metastasis.
(vii) It is recommended when tissue margins are not
tumor-free after surgical excision.
(viii) Adjuvant radiotherapy should be recommended in all
patients affected by aggressive SCCs with perineural
invasion and for individuals who have undergone
lymph node dissection with nodal disease of the head
and neck region [26].
(ix) It is recommended in case of SCCs involving prob-
lematic sites such as the face or hands.
(x) Finally, radiotherapy should be considered in immu-
nosuppressed patients.
Radiotherapy is not recommended in verrucous SCCs [29],
in patients with genodermatoses predisposing to skin cancers
such as xeroderma pigmentosum or Gorlin-Goltz syndrome,
and in patient with connective tissue disease (e.g., systemic
sclerosis).
Radiotherapy is contraindicated on photodamaged skin
and in previously irradiated areas, for cSCCs localized in
poorly vascularized or traumatized sites and for advanced
lesions invading bones, joints, or tendons [27].
Acute and chronic side effects (radiodermatitis) are com-
monly associated with radiotherapy administration, the latter
including pigmentary changes, atrophy, hair loss, fibrosis,
lymphedema, and telangiectasia.Their incidence depends on
the treated area and the regimen of radiotherapy adminis-
tered; hyperfractionated schedules are usually associatedwith
a lower occurrence of late side effects and vice versa [30, 31].
2.4. Cryosurgery. Cryosurgery is based on the application of
liquid nitrogen at−196.5∘C to destroy tumor cells through the
direct effect of freezing and vascular stasis.
Tissue damage depends on intracellular and extracellular
crystals formation.
For cSCC, a rapid cooling is preferred since it leads to
faster intracellular crystal formation that results in better
destruction of tumor cells.
After treatment, patients may exhibit vesiculation, ery-
thema, exudation, and edema, but after a 4- to 6-week period
the damaged area usually heals without sequelae.
Hypopigmentation is the main side effect of cryosurgery
due to melanocytes destruction during freezing.
This method is recommended for treating cSCCs with
well-defined borders in elderly and disable patients.
2.5. Curettage and Electrodesiccation. Curettage and elec-
trodesiccation is a destructive technique often used to treat
superficial low risk cSCCs on the trunk and extremities,
namely, very differentiated forms. It is preferred in elderly
people. After a local anesthesia, the friable tumor tissue is
scraped away by curettage and then the area is electrodesic-
cated to cause necrosis of residual cells.
For superficial lesions, one cycle may suffice. The area
then heals by second intention, which usually results in a pink
to white roundish scar.
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Similarly to cryosurgery, this approach does not permit
histologic examination and it is not recommended for high
risk tumors, lesions larger than 2 cm in diameter, or recurrent
tumors [32].
2.6. Chemotherapy
2.6.1. Oral Chemotherapy. Capecitabine is an oral prodrug of
5-FU thatmay be a valuable substitute of infusional 5- FU [33,
34]. Cartei et al. [35] prospectively investigated the efficacy
of oral capecitabine in 14 patients with SCC that had not
been eradicated by surgery, radiotherapy, and topical 5-FU
(Figures 5(a), 5(b), and 5(c)).
The low-dose of capecitabine administrated resulted in
appreciable improvement in 5 patients and arrested tumor
growth in 4 patients.
2.6.2. Intravenous Chemotherapy. Intravenous chemotherapy
may be used for SCC in patients with distantmetastasis, when
surgery and radiotherapy failed or when these treatment are
contraindicated.
Platinum compounds represent the standard choice;
besides they have been combined with paclitaxel [36], 5-FU
[37], and adriamycin [38].
In 1999 Denic et al. combined platinum compounds with
bleomycin in patients with inoperable SCCs. This combina-
tion resulted in improved tumor resectability in 2 out of 3
patients, including one patient with xeroderma pigmentosum
[39].
A recent comparative study reported cisplatin as a pro-
mising agent for the treatment of local invasive cutaneous
squamous cell carcinoma with respect to the 5-fluorouracil.
An optimal cisplatin-based chemotherapy might provide a
better outcome in patients with an invasive cSCC rather than
surgery [40].
Also combined use of chemotherapy and local therapy
(surgery and/or radiotherapy) has been described [41–43];
in particular, chemotherapy has been used in a neoadjuvant
setting.
Furthermore, palliative chemotherapy combined with
radiotherapy in patients affected by mucosal SCCs of head
and neck showed higher survival rates compared to radio-
therapy alone [44, 45].
Amulticenter study involving patients with advanced pri-
mary, recurrent, or metastatic skin tumors of the extremities,
including 12 SCCs, showed that hyperthermic isolated limb
perfusion with tumor necrosis factor alpha (TNF-alpha),
interferon gamma (IFN-gamma), and melphalan improved
the locoregional control of the disease, saving the majority
of patients from limb amputation [46].
2.7. Electrochemotherapy. This procedure involving electro-
poration combined with antineoplastic drug can represent
a new conservative option for the treatment of extensive
cSCC in which surgical procedures would have entailed wide
tissue sacrifice. A retrospective single-center study enrolling
22 patients showed responses in 18 (81.8%) patients, assessing
the safety and effectiveness of this procedures [33].
2.8. Biological Response Modifiers (BRMs). Biological re-
sponse modifiers (BRMs) have been used in oncology to in-
crease host antitumor immune activity. In SCC, there is lack
of data about the use of BRMs for advanced stages.
Because in vitro studies demonstrated synergismbetween
retinoids and interferons [47], these agents have been used in
combination. In particular, two phase II studies employing
a combination of interferon alpha-2a and 13-cis-retinoid (13-
cRA), with or without cisplatin, showed some clinical activity
in extensive locally advanced tumors [34, 37].
In literature, the concurrent use of BRMs and chemother-
apy has been investigated [48]. Shin et al. [49] conducted a
phase II trial combining interferon alfa and cisplatin with
13-cRA in patients with locally advanced SCC; the 67% of
patients showed an effective clinical improvement with a
median duration of 35 months.
Some patients referred mucocutaneous dryness, mild to
moderate fatigue, andmoderate to severe neutropenia during
BMRs treatment.
2.9. Targeted Therapy. Epidermal growth factor receptor
(EGFR) is commonly expressed in cutaneous SCC of the face
and trunk, aswell as in lymphnodemetastases; further, EGFR
overexpression has been associated with a worse prognostic
outcome [50].
Cetuximab is a chimeric human and murine anti-EGFR
monoclonal antibody, currently approved for the treatment of
metastatic head and neck SCCs; on the contrary its use as
second line treatments after mono- or polychemotherapy
failure is discussed.
In the EGFR inhibitors group there are also small mole-
cule kinase inhibitors (erlotinib, gefitinib, and dasatinib) that
have been approved for the treatment of head and neck SCC.
In a phase II study on 23 patients with locally aggressive
SCC, the use of gefitinib for 2 cycles as a neoadjuvant
treatment followed by surgery and/or radiotherapy showed
an overall response rate of 45.5%with a 2-year disease specific
survival rate of 72% and a progression-free survival rate of
63% [51]. Moreover, another phase II study on 36 patients
with unresectable SCC treated with cetuximab reported a
response rate of 25% and a disease stabilization in 42% of
cases [52]. On the other hand, a randomized phase III study
on 117 patients with metastatic head and neck SCCs revealed
that cetuximab combined with a standard regimen of cis-
platin improved response rates but did not have any a signi-
ficant effect on overall and progression-free survival [53].
In conclusion, EGFR inhibitormay constitute an interest-
ing therapeutic option, but literature data are still insufficient
and this approach is currently under evaluation.
2.10. New Compounds under Study
2.10.1. Herbacetin. Herbacetin is a flavonol compound that is
found in plants; it possesses a strong antioxidant capacity and
exerts anticancer effects on colon and breast cancer. Recently
in vivo and in vitro studies on cSCC and melanoma cell
growth have been carried out identifying herbacetin as a dual
V-akt murine thymoma viral oncogene homolog (AKT) and
ornithine decarboxylase (ODC) inhibitor.
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Figure 5: Before (a), during (b), and after (c) treatment with 5-FU of hyperkeratotic extensive squamous cell carcinoma.
Results of cell-based assays showed that herbacetin inhib-
its neoplastic transformation of cutaneous SCC and melano-
ma cells.These preliminary results need further clinical inves-
tigations [54].
2.10.2. Wool Hydrolysates. A recent study highlights the
bioactive properties of wool hydrolysates on cSCC cells,
decreasing their number. The authors of the study hypoth-
esize that wool hydrolysates may be promising agents to be
used topically for treatment of transformed keratinocytes
in actinic keratosis and invasive squamous skin cancer in
humans [55].
2.10.3. Immunotherapy: Future Perspectives and Ongoing Tri-
als. The role of immunotherapy in the treatment of squa-
mous cell carcinoma of the skin is under investigation. The
ASCO Post from the ASCO Meeting 2017 reported the first
evidence that PD-1 inhibitors may have a role in the manage-
ment of advanced cSCC [56]. This was a very early report,
whose promising results need to be confirmed by larger
scale studies. REGN2810, a fully humanmonoclonal antibody
targeting PD-1, was well tolerated in patients with advanced
cSCC.A pivotal trial of REGN2810 for patients with advanced
CSCC is ongoing (NCT02760498), so the results from this
trial will further elucidate these previous interesting results.
3. Discussion
cSCC is the second most common skin cancer worldwide.
A well-established relationship exists between cSCC and
ultraviolet (UV) radiation, especially UVB. Arsenic exposure
and the human papilloma virus (types 6, 11, and 16) are
other risk factors associated. Among NMSC, cSCC has a
greater propensity for invasive behaviour and metastasis.
cSCC involving the scalp, forehead, ears, nose, and lips has
the highest risk of metastasis such as undifferentiated lesions
greater than 6mm thick that have proceeded to invade deeper
structures, including the musculature, perichondrium, or
periosteum [57].
Surgery is the primary means of treatment for squamous
cell carcinoma of the skin.
Mohs’ micrographic surgery is the treatment of choice for
squamous cell carcinoma of the head and neck, in immuno-
suppressed patients, recurrent squamous cell carcinoma,
squamous cell carcinoma with aggressive histologic features,
and squamous cell carcinoma greater than or equal to 2mm
of depth.The American Academy of Dermatology guidelines
help select those cases that would most benefit from the
Mohs procedure, while conserving healthcare expenditures
[58]. For in situ disease, electrodesiccation with curettage, or
topical treatment with 5FU, imiquimod, and photodynamic
therapy have been used successfully [59].
Radiation therapy is likely most beneficial in the adjuvant
setting for high risk cSCC on head neck and mucosa.
Chemotherapy is typically best reserved for patients with
metastatic or locally advanced disease that is not controllable
with surgical and/or radiation therapies. EGFR inhibitors and
immunotherapies are newer targeted treatments and may
offer greater efficacy in these settings [60].
Patients with a history of a few squamous cell carcinomas
and some actinic keratoses may be followed every six to 12
months, while those with many squamous cell carcinomas or
aggressive tumors likely will need to be seenmuchmore often
[59].
Selecting the most appropriate therapeutic strategy, the
clinical and histological features of the lesion, the patient
aspect and the body area involved should be considered.Non-
surgical therapies can be used in elderly patients with comor-
bidity and nonaggressive tumors. Lesions arising on mucosa
and nearby sense organs benefit from more aggressive treat-
ments and closer follow-up. The surgical treatments of the
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head-neck district require high surgical skills in order to
guarantee radicality of the surgical excision and conservation
of the aesthetic-functional units of the treated area. In the case
of demolition therapies such as electrodesiccation and laser
therapy, it is recommended to previously perform biopsy
with histological verification in order to limit legal medi-
cal controversies.
4. Conclusions
Skin carcinogenesis is a multistep process with several stages
along its malignant evolution.
cSCC can be invasive or not, requiring these forms differ-
ent approaches. To date, surgery is still considered as the gold
standard approach for invasive cSCC therapy. Metastasis to
regional lymph nodes occurs in approximately 5% of cases
and treatment involves a combination of surgery and adju-
vant radiation. Nevertheless, in recent years new nonsurgical
modalities have shown high efficacy rates and could be
considered in selected cases, such as elderly and/or disable
patients when surgery is contraindicated [61]. New insights
from Genome-wide association studies (GWAS) identifying
genetic loci associated with cutaneous squamous cell carci-
noma (cSCC) risk and invasivenessmay help identify individ-
uals at higher risk for developing clinically aggressive cSCC.
These interventions will guide the sparing of surgical inter-
vention. Moreover novel agents, such as herbacetin and wool
hydrolysates, are currently under investigation. miRNA rep-
resents a potential biomarker along the malignant evolution
of keratinocytes towards cSCC and further studies on this
interesting and promising field are warranted [62, 63].
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perspectives on role of tumor microenvironment in progres-
sion of cutaneous squamous cell carcinoma,” Cell and Tissue
Research, vol. 365, no. 3, pp. 691–702, 2016.
[7] J. J. Bonerandi, C. Beauvillain, L. Caquant et al., “Guidelines
for the diagnosis and treatment of cutaneous squamous cell
carcinoma and precursor lesions,” Journal of the European
Academy of Dermatology and Venereology, vol. 25, no. 5, pp. 1–
51, 2011.
[8] M. M. Hartevelt, J. N. Bouwes Bavinck, A. M. Kootte, B. J. Ver-
meer, and J. P. Vandenbroucke, “Incidence of skin cancer after
renal transplantation in the Netherlands,” Transplantation, vol.
49, no. 3, pp. 506–509, 1990.
[9] F. J. Moloney, H. Comber, P. O’Lorcain, P. O’Kelly, P. J. Conlon,
and G. M. Murphy, “A population-based study of skin cancer
incidence and prevalence in renal transplant recipients,” British
Journal of Dermatology, vol. 154, no. 3, pp. 498–504, 2006.
[10] L. Peng, Y. Wang, Y. Hong et al., “Incidence and relative risk
of cutaneous squamous cell carcinoma with single-agent BRAF
inhibitor and dual BRAF/MEK inhibitors in cancer patients: a
meta-analysis,”Oncotarget, vol. 8, no. 47, pp. 83280–83291, 2017.
[11] K. Rubin, “MAPK pathway-targeted therapies: care and man-
agement of unique toxicities in patients with advanced
melanoma,” Clinical Journal of Oncology Nursing, vol. 21, no. 6,
pp. 699–709, 2017.
[12] A. Lomas, J. Leonardi-Bee, and F. Bath-Hextall, “A systematic
review of worldwide incidence of nonmelanoma skin cancer,”
British Journal of Dermatology, vol. 166, no. 5, pp. 1069–1080,
2012.
[13] B. L. Diffey and J. A. A. Langtry, “Skin cancer incidence and the
ageing population,” British Journal of Dermatology, vol. 153, no.
3, pp. 679-680, 2005.
[14] J.-C. Martinez and C. C. Otley, “Themanagement of melanoma
and nonmelanoma skin cancer: a review for the primary care
physician,” Mayo Clinic Proceedings, vol. 76, no. 12, pp. 1253–
1265, 2001.
[15] I. Ahmed, J. Berth-Jones, S. Charles-Holmes, C. J. O’Callaghan,
and A. Ilchyshyn, “Comparison of cryotherapy with curettage
in the treatment of Bowen’s disease: a prospective study,” British
Journal of Dermatology, vol. 143, no. 4, pp. 759–766, 2000.
[16] D. G. Brodland and J. A. Zitelli, “Surgical margins for excision
of primary cutaneous squamous cell carcinoma,” Journal of the
AmericanAcademy of Dermatology, vol. 27, no. 2, part 1, pp. 241–
248, 1992.
[17] H. Breuninger, T. Eigentler, and F. Bootz, “Brief guidelines—
cutaneous squamous cell carcinoma,” Journal of the German
Society of Dermatology, p. 10, 2012.
[18] J. A. Neville, E. Welch, and D. J. Leffell, “Management of non-
melanoma skin cancer in 2007,” Nature Clinical Practice Oncol-
ogy, vol. 4, no. 8, pp. 462–469, 2007.
[19] M. R. T. M.Thissen, M. H. A. Neumann, and L. J. Schouten, “A
systematic review of treatment modalities for primary basal cell
carcinomas,” JAMA Dermatology, vol. 135, no. 10, pp. 1177–1183,
1999.
[20] T. H. Nguyen and D. Q.-D. Ho, “Nonmelanoma skin cancer,”
Current Treatment Options in Oncology, vol. 3, no. 3, pp. 193–
203, 2002.
[21] National Comprehensive Cancer Network, “Clinical practice
guidelines in oncology. Basal cell and squamous cellskin can-
cers,” http://www.nccn.org/professionals/physician gls/f guide-
lines.asp.
8 BioMed Research International
[22] Non melanoma skin cancer: guidelines for treatment and
management in Australia. Clinical practice Guidelines,
National Healt medical research Council, Camberra, Australia,
2002, https://www.nhmrc.gov.au/guidelines-publications/re-
scinded-guidelines.
[23] R.Motley, P. Kersey, andC. Lawrence, “Multiprofessional guide-
lines for themanagement of the patient with primary cutaneous
squamous cell carcinoma,” British Journal of Dermatology, vol.
146, no. 1, pp. 18–25, 2002.
[24] H. W. Randle, “Basal cell carcinoma: Identification and treat-
ment of the high-risk patient,”Dermatologic Surgery, vol. 22, no.
3, pp. 255–261, 1996.
[25] R. Pampena, T. Palmieri, A. Kyrgidis et al., “Orthovoltage radio-
therapy for nonmelanoma skin cancer (NMSC): comparison
between 2 different schedules,” Journal of the American Acad-
emy of Dermatology, vol. 74, no. 2, pp. 341–347, 2016.
[26] “Basal cell and squamous cell skin cancers. NCCN clinical
practice guidelines in oncology (NCCN Guidelines) Version I,”
2013, http://www.nccn.org/professionals/physician gls/f guide-
lines.asp.
[27] L. Lansbury, F. Bath-Hextall, W. Perkins, W. Stanton, and J.
Leonardi-Bee, “Interventions for non-metastatic squamous cell
carcinoma of the skin: systematic review and pooled analysis of
observational studies,” BMJ, vol. 347, article f6153, 2013.
[28] M. J. Veness, “The important role of radiotherapy in patients
with non-melanoma skin cancer and other cutaneous entities,”
Journal of Medical Imaging and Radiation Oncology, vol. 52, no.
3, pp. 278–286, 2008.
[29] E. Rio, E. Bardet, C. Ferron et al., “Interstitial brachytherapy of
periorificial skin carcinomas of the face: a retrospective study
of 97 cases,” International Journal of Radiation Oncology Biology
Physics, vol. 63, no. 3, pp. 753–757, 2005.
[30] N. Voss and C. Kim-Sing, “Radiotherapy in the treatment of
dermatologic malignancies,”Dermatologic Clinics, vol. 16, no. 2,
pp. 313–320, 1998.
[31] M. K. Silverman, A. W. Kopf, A. H. Gladstein, R. S. Bart, C. M.
Grin, and M. J. Levenstein, “Recurrence rates of treated basal
cell carcinomas: part 4: X-ray therapy,”The Journal of Dermato-
logic Surgery and Oncology, vol. 18, no. 7, pp. 549–554, 1992.
[32] K. P. An and D. Ratner, “Surgical management of cutaneous
malignancies,” Clinics in Dermatology, vol. 19, no. 3, pp. 305–
320, 2001.
[33] S. C. R. Oliveira, C. M. V. Moniz, R. Riechelmann et al., “Phase
II study of capecitabine in substitution of 5-FU in the chemora-
diotherapy regimen for patients with localized squamous cell
carcinoma of the anal canal,” Journal of Gastrointestinal Cancer,
vol. 47, no. 1, pp. 75–81, 2016.
[34] B. Endrizzi, R. L. Ahmed, T. Ray, A. Dudek, and P. Lee,
“Capecitabine to reduce nonmelanoma skin carcinoma burden
in solid organ transplant recipients,” Dermatologic Surgery, vol.
39, no. 4, pp. 634–645, 2013.
[35] G. Cartei, F. Cartei, G. Interlandi et al., “Oral 5-Fluorouracil
in squamous cell carcinoma of the skin in the aged,” American
Journal of Clinical Oncology, vol. 23, no. 2, pp. 181–184, 2000.
[36] K. G. Lewis, M. D. Lewis, L. Robinson-Bostom, and T. D.
Pan, “Inflammation of actinic keratoses during capecitabine
therapy,” JAMA Dermatology, vol. 140, no. 3, pp. 367-368, 2004.
[37] A. D. Colevas, S. Adak, P. C. Amrein, J. J. Barton, R. Costello,
and M. R. Posner, “A phase II trial of palliative docetaxel plus
5-fluorouracil for squamous-cell cancer of the head and neck,”
Annals of Oncology, vol. 11, no. 5, pp. 535–539, 2000.
[38] P. M. Hoff, R. Ansari, G. Batist et al., “Comparison of oral
capecitabine versus intravenous fluorouracil plus leucovorin as
first-line treatment in 605 patients with metastatic colorectal
cancer: results of a randomized phase III study,” Journal of
Clinical Oncology, vol. 19, no. 8, pp. 2282–2292, 2001.
[39] S. Denic, “Preoperative treatment of advanced skin carcinoma
with cisplatin and bleomycin,” American Journal of Clinical
Oncology, vol. 22, no. 1, pp. 32–34, 1999.
[40] T. Khansur and A. Kennedy, “Cisplatin and 5-fluorouracil for
advanced locoregional andmetastatic squamous cell carcinoma
of the skin,” Cancer, vol. 67, no. 8, pp. 2030–2032, 1991.
[41] O. Merimsky, M. Neudorfer, E. Spitzer, and S. Chaitchik, “Sal-
vage cisplatin and adriamycin for advanced or recurrent basal
or squamous cell carcinoma of the face,”Anti-Cancer Drugs, vol.
3, no. 5, pp. 481–484, 1992.
[42] R. Phan, L. Phan, L. E. Ginsberg, G. Blumenschein, M. D.
Williams, and B. Esmaeli, “Durable response to chemotherapy
for recurrent squamous cell carcinoma of the cheek with
perineural spread,” JAMA Ophtalmology, vol. 127, no. 8, pp.
1074-1075, 2009.
[43] T. H. Guthrie and E. S. Porubsky, “Successful systemic chemo-
therapy of advanced squamous and basal cell carcinoma of the
skin with cis-diamminedichloroplatinum iii and doxorubicin,”
The Laryngoscope, vol. 92, no. 11, pp. 1298-1299, 1982.
[44] T. H. Guthrie, L. J. McElveen, E. S. Porubsky, and J. D. Harmon,
“Cisplatin and doxorubicin. An effective chemotherapy combi-
nation in the treatment of advanced basal cell and squamous
carcinoma of the skin,” Cancer, vol. 55, no. 8, pp. 1629–1632,
1985.
[45] T. H. Guthrie Jr., E. S. Porubsky, M. N. Luxenberg, K. J. Shah, K.
L. Wurtz, and P. R. Watson, “Cisplatin-based chemotherapy in
advanced basal and squamous cell carcinomas of the skin:
results in 28 patients including 13 patients receiving multi-
modality therapy,” Journal of Clinical Oncology, vol. 8, no. 2, pp.
342–346, 1990.
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